<--- Back to Details
First PageDocument Content
Transcription factors / Epithelialmesenchymal transition / Tissue transglutaminase / Cancer stem cell / CDH1 / NF-B / C-jun / Metastatic breast cancer / Tumor microenvironment / Hypoxia-inducible factors / RHOA / C-Met
Date: 2014-07-02 01:39:52
Transcription factors
Epithelialmesenchymal transition
Tissue transglutaminase
Cancer stem cell
CDH1
NF-B
C-jun
Metastatic breast cancer
Tumor microenvironment
Hypoxia-inducible factors
RHOA
C-Met

Agnihotri et al. Breast Cancer Research 2013, 15:202 http://breast-cancer-research.com/contentREVIEW Tissue transglutaminase as a central mediator in

Add to Reading List

Source URL: www.icmr.nic.in

Download Document from Source Website

File Size: 1,80 MB

Share Document on Facebook

Similar Documents

Bioluminescent orthotopic PDX models of primary pancreatic cancer and residual/metastatic breast cancer to predict efficacy of standard of care and experimental treatments Benjamin G. 1 Cuiffo ,

Bioluminescent orthotopic PDX models of primary pancreatic cancer and residual/metastatic breast cancer to predict efficacy of standard of care and experimental treatments Benjamin G. 1 Cuiffo ,

DocID: 1uQqF - View Document

Jose Falcon Father, Co-Survivor and Veteran Tour de Pink Rider My name is Jose Falcon and I am the proud father and caregiver to my only daughter, Kayla Falcon. She was diagnosed with Stage 4 Metastatic breast cancer at

Jose Falcon Father, Co-Survivor and Veteran Tour de Pink Rider My name is Jose Falcon and I am the proud father and caregiver to my only daughter, Kayla Falcon. She was diagnosed with Stage 4 Metastatic breast cancer at

DocID: 1trwM - View Document

· METASTATIC BREAST CANCER ·  Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD  Abstract

· METASTATIC BREAST CANCER · Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD Abstract

DocID: 1rmV3 - View Document

Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

DocID: 1riiF - View Document

Media release, October 23, 2014  Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

Media release, October 23, 2014 Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

DocID: 1rf3r - View Document